Insilico Medicine, the biotech company with twin headquarters in Boston and Hong Kong, said it’s the first time an AI-created ...

Insilico plans late-stage trials for rentosertib following positive mid-stage safety and efficacy data for idiopathic ...

SMMT's HARMONi trial shows PFS benefits for ivonescimab in EGFR-mutant NSCLC, but lack of proven overall survival raises ...

Artificial intelligence (AI) is rapidly transforming the pharmaceutical industry, reshaping the landscape from target identification to personalized ...

Results from a phase 3 clinical trial published in the New England Journal of Medicine, today (June 2nd) show that patients ...

Summit Therapeutics' recent stock sell-off reflects regulatory uncertainty rather than drug failure. Click here to read an ...

Results from a Phase III clinical trial published in the New England Journal of Medicine, show that patients with lung cancer ...

In patients with lung cancer, more patients managed with current vs. more intensive surveillance guidelines for small ...

Results from three trials continue to demonstrate the potential of DATROWAY® (datopotamab deruxtecan) in combination with ...

In response to his good fortune, Roy has committed to leaving an endowment gift to the BC Cancer Foundation, to support further cancer treatment research, so others can benefit as he has done from ...

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top ...

It can affect your breathing. Sometimes the lung inflammation gets better on its own without treatment. But some people have an aggressive form of the disease. This causes lifelong (permanent) loss of ...